Format

Send to

Choose Destination
Br J Clin Pharmacol. 2017 May;83(5):1143-1145. doi: 10.1111/bcp.13218. Epub 2017 Mar 19.

Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer.

Author information

1
Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
2
BC Children's Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.
3
Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
4
Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
5
Department of Pediatrics, University of Western Ontario, London, Ontario, Canada.
6
Department of Pediatrics, Division of Cardiology, Stanford University, Stanford, California, USA.
7
Teva Pharmaceutical Industries, Petach Tikva, Israel.
8
University Institute of Clinical Chemistry, Inselspital Bern University Hospital and University of Bern, Switzerland.
9
Division of Translational Therapeutics, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.

KEYWORDS:

anthracycline; anthracycline-induced cardiotoxicity; cancer; chemotherapy; clinical practice guidelines; congestive heart failure; pharmacogenomic screening

PMID:
28317142
PMCID:
PMC5401971
DOI:
10.1111/bcp.13218
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center